Anidulafungin + Fluconazole
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Candidemia
Conditions
Candidemia
Trial Timeline
Feb 1, 2009 → Feb 1, 2018
NCT ID
NCT00761267About Anidulafungin + Fluconazole
Anidulafungin + Fluconazole is a phase 3 stage product being developed by Pfizer for Candidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00761267. Target conditions include Candidemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00761267 | Phase 3 | Completed |
| NCT00056368 | Phase 3 | Completed |
Competing Products
9 competing products in Candidemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| micafungin + Micafungin + Caspofungin | Astellas Pharma | Approved | 85 |
| Micafungin | Astellas Pharma | Approved | 85 |
| AmBisome | Gilead Sciences | Approved | 84 |
| Anidulafungin/Fluconazole | Pfizer | Phase 3 | 76 |
| Anidulafungin + Voriconazole | Pfizer | Approved | 84 |
| Anidulafungin | Pfizer | Phase 3 | 76 |
| Fosmanogepix + Fosmanogepix + Caspofungin + Fluconazole + Placebo + Placebo + Placebo + Placebo | Basilea Pharmaceutica | Phase 3 | 72 |
| APX001 | Basilea Pharmaceutica | Phase 2 | 47 |
| APX001 | Basilea Pharmaceutica | Phase 2 | 47 |